Paralleling with the improvement of RA disease activity, in spite of the relatively small sample size, the relevance of inhibiting JAK/STAT pathway by tofacitinib could be suggested in RA patients with T2D. This evidence concerns the gene SOAT1 and type 2 diabetes mellitus.